Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights

The introduction of tyrosine kinase inhibitors (TKIs) has changed the treatment paradigm of chronic myeloid leukemia (CML), leading to a dramatic improvement of the outcome of CML patients, who now have a nearly normal life expectancy and, in some selected cases, the possibility of aiming for the mo...

Full description

Saved in:

Bibliographic Details
Published in:	Cells (Basel, Switzerland) Vol. 12; no. 13; p. 1703
Main Authors:	Iezza, Miriam, Cortesi, Sofia, Ottaviani, Emanuela, Mancini, Manuela, Venturi, Claudia, Monaldi, Cecilia, De Santis, Sara, Testoni, Nicoletta, Soverini, Simona, Rosti, Gianantonio, Cavo, Michele, Castagnetti, Fausto
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 23-06-2023 MDPI
Subjects:	Age Analysis Blast Crisis Chemotherapy Chromosome Aberrations Chronic myeloid leukemia Comorbidity Cytogenetics Drug therapy genomic factors Health risk assessment Humans Kinases Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Life span Medical prognosis Methods Myeloid leukemia Patients Pediatrics Prognosis Protein-tyrosine kinase Remission Remission (Medicine) Response rates Review Risk Assessment Spleen Transplants & implants Italy risk assessment chronic myeloid leukemia prognosis genomic factors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!